Morning Buzz: PharMerica (NYSE:PMC), Array BioPharma (NASDAQ:ARRY), Mobile Mini (NASDAQ:MINI), Genocea Biosciences, Inc. (NASDAQ:GNCA), Health Care REIT, Inc. (NYSE:HCN)

PharMerica Corporation (NYSE:PMC) reported its financial results for the second quarter and six months ended June 30, 2014. Revenues for the second quarter of 2014 were $448.6 million compared with $430.8 million for the second quarter of 2013. The increase in revenue was primarily the result of the fourth quarter 2013 acquisitions and branded drug…

Read More

5 Stocks Under Wall Street’s Radar: CBD Energy (NASDAQ:CBDE), Evoke Pharma (NASDAQ:EVOK), ULTA Salon, Cosmetics & Fragrance (NASDAQ:ULTA), Medgenics, Inc. (NYSEMKT:MDGN), Aluminum (NYSE:ACH)

CBD Energy Limited (NASDAQ:CBDE), a diversified clean energy company and leading global provider of solar systems, has, through its Australian Energy Efficiency subsidiary, Parmac, been awarded installation and maintenance contracts in Melbourne, Australia. The total estimated value of the contracts is approximately US$1.7 million. The projects are expected to be commissioned in September and to…

Read More

Momentum Stocks: Lattice Semiconductor (NASDAQ:LSCC), CVS Caremark (NYSE:CVS), Silicom (NASDAQ:SILC), Galena Biopharma, Inc. (NASDAQ:GALE), Alexander & Baldwin, Inc. (NYSE:ALEX)

Lattice Semiconductor Corporation (NASDAQ:LSCC) today announced that it is scheduled to present at Jefferies Semiconductors, Hardware & Communications Infrastructure Summit taking place on Wednesday, August 27th at the Ritz Carlton in Chicago. Lattice Semiconductor Corporation (NASDAQ:LSCC) belongs to Technology sector. Its net profit margin is 10.50% and weekly performance is 4.81%. On last trading day…

Read More
Biotech stock market news

Biotech Stocks Highlights: A look at Last Week’s Performance

With second quarter earnings season coming to an end, focus in the biotech sector is back on pipeline and regulatory updates. Last week’s highlights included Achillion Pharmaceuticals, Inc.’s (ACHN) impressive interim data on its experimental hepatitis C virus (HCV) treatment, Gilead Sciences’ (GILD – Analyst Report) legal victory and Amgen’s (AMGN – Analyst Report) hit…

Read More